This research develops a hybrid drug for dry age-related macular degeneration, combining anti-inflammatory and antioxidant mechanisms. By targeting both inflammation and oxidative stress, it aims to slow disease progression more effectively than existing treatments. Laboratory models test whether the combined therapy outperforms individual or co-administered components in preserving retinal function.

Corneal scarring causes widespread vision loss and is poorly treated by transplantation alone. This research develops a bioengineered corneal glue that both seals and heals wounds by promoting cell infiltration and reducing fibrosis. The approach enables scar-free healing, lowers transplant rejection risk, and offers a regenerative alternative to sutures and conventional sealants.

Presbyopia, the age-related loss of near vision, occurs when the eye’s crystalline lens stiffens. A known lens-softening drug, Bistatin, affects too many eye structures to be safe. This research creates a targeted antibody–drug conjugate that delivers Bistatin only to the lens, restoring flexibility and offering a potential non-surgical treatment.